Related Experiment Video
Updated: Oct 26, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities
Lisa K Stamp1, Hamish Farquhar2, Huai Leng Pisaniello3
1University of Otago, Christchurch, New Zealand. Lisa.Stamp@cdhb.health.nz.
Insights
Managing gout in patients with chronic kidney disease (CKD) is challenging due to limited evidence and conflicting recommendations. This consensus statement highlights research gaps for effective gout and CKD management.
Area of Science:
- Nephrology
- Rheumatology
- Clinical Pharmacology
Background:
- Gout and chronic kidney disease (CKD) frequently coexist, creating management challenges.
- Current evidence guiding gout management in CKD patients is limited, leading to varied treatment approaches.
- Conflicting professional recommendations exacerbate confusion among clinicians regarding gout and CKD treatment.
Framework:
- This consensus statement by the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) analyzes existing evidence on gout management in CKD.
- It identifies critical research gaps concerning both general management strategies and specific urate-lowering therapies (ULTs) and flare treatments.
- The statement is supported by G-CAN systematic literature reviews, focusing on safety and efficacy data.
Implementation:
- The document critically examines the use of urate-lowering therapy (ULT) in advanced CKD.
- It discusses the safety and efficacy of various medications used for gout flares and ULT.
- Key areas for future research are identified to address the lack of robust evidence.
Implications:
- Clarifies the current state of knowledge regarding gout management in CKD patients.
- Provides a research agenda to guide future studies on optimal treatment strategies.
- Aims to reduce clinical confusion and improve patient care for those with coexisting gout and CKD.
Abstract:
Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Urinary Tract Calculi III: Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations

